Farewell Harry!
When Harry Schwartz joined Pharmaceutical Executive for its inaugural issue in January 1981, he had already written 19 books and was well-known for his medical-related writings in the New York Times and other publications. Every month since then, without fail, he has faithfully supplied his At Large column, with its far-ranging analysis and commentary on political and business trends that affect the industry. Every magazine changes over time, and now a series of changes has brought an end to that distinguished, 20-year-long contribution.
When Harry Schwartz joined Pharmaceutical Executive for its inaugural issue in January 1981, he had already written 19 books and was well-known for his medical-related writings in the New York Times and other publications. Every month since then, without fail, he has faithfully supplied his At Large column, with its far-ranging analysis and commentary on political and business trends that affect the industry. Every magazine changes over time, and now a series of changes has brought an end to that distinguished, 20-year-long contribution.
This month, we mark the retirement of At Large to make room for new editorial features we believe will improve our service to readers. We are deeply indebted to Harry Schwartz for his valuable work over the years, and we know many readers will miss his staunch arguments in defense of the industry's interests. Soon a new column, At Issue, will offer a greater opportunity for others to speak on vital industry issues. We invite our readers to contribute their thoughts and ideas for that feature by contacting our managing editor, Judy Sawyer, directly.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
